Niagen Bioscience (NAGE) FDA Approvals $3.47 +0.08 (+2.36%) Closing price 04:00 PM EasternExtended Trading$3.46 -0.01 (-0.14%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Niagen Bioscience's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Niagen Bioscience (NAGE). Over the past two years, Niagen Bioscience has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as NB4168. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. NB4168 FDA Regulatory Events NB4168 is a drug developed by Niagen Bioscience for the following indication: Treatment Of Ataxia Telangiectasia. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Designation Grant - July 13,2026Designation Grant RPD DesignationDrug: NB4168Announced Date: July 13, 2026Indication: Treatment Of Ataxia TelangiectasiaAnnouncementNNiagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia TelangiectasiaAI SummaryNNiagen Bioscience said its drug candidate NB4168 received Rare Pediatric Disease designation from the U.S. Food and Drug Administration for the treatment of ataxia telangiectasia, a rare and serious disease that mainly affects children. The company said the recognition supports its plan to develop a therapy for a condition with no approved treatments. It also sees the designation as an important sign of support for NB4168 and its broader work in rare disease medicines. Ataxia telangiectasia is a progressive disorder that can cause trouble with movement, immune problems, and other health issues. NNiagen Bioscience said the FDA designation may help speed development and give the program added visibility. The company said it believes NB4168 could become an important new option for patients and families facing this unmet medical need.Read Announcement Niagen Bioscience FDA Events - Frequently Asked Questions Has Niagen Bioscience received FDA approval? As of now, Niagen Bioscience (NAGE) has not received any FDA approvals for its therapy in the last two years. What drugs has Niagen Bioscience submitted to the FDA? In the past two years, Niagen Bioscience (NAGE) has reported FDA regulatory activity for NB4168. What is the most recent FDA event for Niagen Bioscience? The most recent FDA-related event for Niagen Bioscience occurred on July 13, 2026, involving NB4168. The update was categorized as "Designation Grant," with the company reporting: "NNiagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia Telangiectasia" What conditions do Niagen Bioscience's current drugs treat? Currently, Niagen Bioscience has one therapy (NB4168) targeting the following condition: Treatment Of Ataxia Telangiectasia. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Aligos Therapeutics FDA EventsANI Pharmaceuticals FDA EventsArtelo Biosciences FDA EventsBioMarin Pharmaceutical FDA EventsEnlivex Therapeutics FDA EventsPrima BioMed FDA EventsIncyte FDA EventsIonis Pharmaceuticals FDA EventsNiagen Bioscience FDA EventsOcugen FDA EventsOncolytics Biotech FDA EventsQ32 Bio FDA EventsVoyager Therapeutics FDA EventsBristol Myers Squibb FDA EventsBiogen FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Vor Biopharma FDA Events Sana Biotechnology FDA Events Solid Biosciences FDA Events Olema Pharmaceuticals FDA Events Kura Oncology FDA Events BioAge Labs FDA Events Avalo Therapeutics FDA Events Arbutus Biopharma FDA Events Janux Therapeutics FDA Events Pharming Group FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:NAGE last updated on 7/13/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Designation Grant - July 13,2026Designation Grant RPD DesignationDrug: NB4168Announced Date: July 13, 2026Indication: Treatment Of Ataxia TelangiectasiaAnnouncementNNiagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia TelangiectasiaAI SummaryNNiagen Bioscience said its drug candidate NB4168 received Rare Pediatric Disease designation from the U.S. Food and Drug Administration for the treatment of ataxia telangiectasia, a rare and serious disease that mainly affects children. The company said the recognition supports its plan to develop a therapy for a condition with no approved treatments. It also sees the designation as an important sign of support for NB4168 and its broader work in rare disease medicines. Ataxia telangiectasia is a progressive disorder that can cause trouble with movement, immune problems, and other health issues. NNiagen Bioscience said the FDA designation may help speed development and give the program added visibility. The company said it believes NB4168 could become an important new option for patients and families facing this unmet medical need.Read Announcement
